Journal of Vaccines & Vaccination
ISSN: 2157-7560
Corocleanu, J Vaccines Vaccin 2012, 3:8
DOI: 10.4172/2157-7560.1000163
Review Article
Open Access

Embryonic-Like Stem Cells Derived from Postpartum Placenta Delivered After Spotaneous Labor Emerging as Universal Prophylactic Cancer Vaccine

Manole Corocleanu*
Obstetric and Gynecologic Hospital, Brasov, Romania

Abstract

In the eighth decade of the last century extensive clinical delayed-type hypersensitivity (DTH) skin tests to an intradermal injection of a pharmaceutical allogeneic human Placenta Suspension (phPS) performed in obstetrical, gynecological and control group patients have shown positive reaction in 239 patients with clinical conditions having as histopathological substratum a hypoxia-induced adaptive/reactive epithelial cell proliferation, e.g. syncytiotrophoblastic cell hyperplasia, endometrial cell hyperplasia, or different gynecological cancers.

Because the immune response against phPS have shown antigenc similarities between normal placental and endometrial hyperplastic cells and different kind of cancer cells and because many cancers adopt an embryonic stem-like gene expression pattern, it is suggested that the profile of hypoxia- promoting placental and endometrial stem cell proliferation is more embryonic-like, and that the immune respose against phPS is expected to cross-react with tumor cells *in vivo*.

Persistent growth and accelerated oxygen consumption by hyperplastic cytotrophoblastic cells and neoplastic cells in a hypoxic microenvironment, a basic shift in energy metabolism is accompanied by appearance of heat shock proteins (HSPs), of fetal isoenzymes and of membrane glycoproteins (reappearance of oncofetal antigens, OFAs), which, as result of their overexpression/amplification may induce a host immunological response.

Thus, it is assuming that phPS prepared from full-term human placentas delivered after a spontaneous labor comprises stem/progenitor cells reverted to a proliferative embryonic stem cell-like-state upon exposure to labor-inducing intermittent placental hypoxia and that by expressing HSP/OFAs could immunize to generate immune response against a variety of antigens that are shared by different kind of epithelial cancers.

This immunological feature of phPS qualifies it as a vaccine-related product that may be used for a preventive cancer vaccine when mixed with a potent adjuvant (BCG-Vaccine) and given normal healthy individuals.

Keywords: Placenta; Embryonic-like stem cells; Preventive cancer vaccine

Introduction

The field of tumor immunology has made awesome headways in late years. A review investigation of our past studies [1] and our recommended pharmaceutical allogeneic human Placenta-Lysates/BCG-vaccine method configure for malignancy anticipation [2], in view of the presumption that placenta portions indistinguishable development components, antigenic determinants, and safe-escape lands with tumor units, joined together with present knowledges might give extra knowledge in this inoculation methodology.

Proteins that are expressed by both malignant and healthy fetal tissues (the placental-fetal complex) are recognized as oncofetal antigens (OFA) These antigens produced in high concentrations in pregnancy and in malignancy by associated with cell proliferation and differentiation [3]. Biological role of antigens in malignancy is suppression of the host's immune system and in pregnacy these antigens will affect the immune response of maternal, generating maternal tolerance towards the embryo. On the other hand, the involvement of oncofetal antigens in both embryonic and malignant development supports the concept that oncofetal antigens may intervene in the control of maternal immune responses during pregnancy, in the manner of the host defense to carcinogenesis [4,5].

Human Embryonic Genes are Re-Expressed in Cancer Cells and are Immunogenic

Monk and Holding [6] have shown that processes occurring during tumorigenesis may be similar to processes occurring in early development. Human preimplantation embryonic units are comparable in phenotype to Cancer cells. Cells experience deprogramming of undifferentiated organism state to end up being potentially immortal and invasive. The precise nature of the launching occasion is obscure in both growth and tumorigenesis transforms, the outcome is far reaching demethylation. Thusly, it may be wanted that tumor cells will express genes in the same manner as these exceptionally early embryonic cells, specifically genes particularly connected with deprogramming and come back to the undifferentiated and proliferative immature microorganism state, and the upkeep of that state.

Recently several laboratories have demonstrated that introduction of just four active genes into a mature differentiated cell can convert it into a cell with embryonic stem cell characteristics [7].

Coggin et al. [8,9] has identified the OFA/iLRP protein and its role as a T-cell inducing and immuno-regulating factor in fetogenesis and oncogenesis. This protein was moreover recognized in promptly

***Corresponding author:** Manole Corocleanu, Paul Richter Str., 500025 Brasov, Romania, E-mail: corocleanu@yahoo.com

Received November 19, 2012; **Accepted** December 15, 2012; **Published** December 19, 2012

Citation: Corocleanu M (2012) Embryonic-Like Stem Cells Derived from Postpartum Placenta Delivered After Spotaneous Labor Emerging as Universal Prophylactic Cancer Vaccine. J Vaccines Vaccin 3:163. doi:10.4172/2157-7560.1000163

to mid development fetal units and rising trophoblast, henceforth the expression "Oncofetal Antigen". It is concluded that OFA/immature LRP, the 37 kDa fetal-restricted molecule, unlike mLRP (mature LRP, MW 67 kDa), is a true "immunogenic". In breast cancer patients, Rohrer et al. established several OFA/iLRP-specific $CD4^+$ and cytotoxic as well as regulatory $CD8^+$ T cell clones. This phenomenon caused by an excess of the T cell immunogenic, 37-44 kDa OFA, enables the immune system to suppress Tc-mediated immunity. In other words, it is an immuno-regulatory controlled measure that prevents over- production of Tc cells to any Tc-antigen. This immuno-regulation prevents anti-self Tc-mediated immunity and other anti-self immunity. The IL-10 restrained Tc movement and so these cells can hose hostile to-tumor safety of whatever specificity.

During tumor development in mice and humans, oncofetal 32-44 kDa Ag/immature laminin receptor (OFA/iLRP)-specific Th1, CTL, and IL-10-secreting T-suppressor cells (Ts) cells are induced. The presence of too many Ts or too few effector T cells appears to predict a poor prognosis [10,11].

The Human Discarded Placentas of Healthy Newborns Comprise Embryonic-Like Stem Cells

Researchers at the University of Pittsburgh (2005) have revealed findings that some placental cells of afterbirth placenta have many of the same characteristics of embryonic stem cells and thus, placenta may yield alternative to embryonic stem cells.

Lee et al. [12] have shown that in addition to hematopoietic stem cells (HSCs), other potential stem cells (SCs), such as mesenchymalSCs (MSCs), unrestricted somatic SCs(USSCs), cord blood-derived embryonic-like SCs (CBEs), and umbilical cord blood (UCB)-derived multipotent progenitor cells (MPCs) have been isolated from Umbilical Cord Blood and characterized.

Cord blood –derived embryonic-like stemcells (CBEs) are newly discovered human cells, these are multipotent non-hematopoietic stem cells. These new cells are more versatile than adult stem cells. And these cells will produce any tissue of the body.

The Human Endometrium Comprises Endometrial Regenerative Cells (ERCs)

Zhong et al. [13] have shown that Endometrial Regenerative Cells (ERCs) are mesenchymal-like cells which have pluripotent differentiation capacity and are identified by unique surface markers and production of growth factor. Embryonic stem cells and mesenchymal stem cells (MSC) derived from bone marrow are similar in pluripotency. Also, stem cells which are derived from endometrial have various characteristics similarly mesenchymal stem cells are included to induce immune modulate, Treg production and neoangiogenesis [14,15].

Hypoxia, Hypoxia-Inducible Factor (HIF) and The Placenta

Adelman et al. [16] have shown that development of placental is influenced by oxygen (O_2) tension. Human cytotrophoblasts undergo proliferation *in vitro* under low O_2 conditions but differentiate at higher O_2 levels, mimicking transition of development undergo as they invade the placental bed to establish *in vivo* maternal–fetal circulation. Hypoxia-inducible factor-1 (HIF-1), consisting of HIF-1α and ARNT subunits which activates many genes involved in response of cellular and organismal to O_2 deprivation.

Placental development is initiated and maintained by the hypoxic uterine environment. Uterine environment is already a hypoxic 3-5% O_2 versus normal physiologic oxygen tension (normoxia) of approximately 8%. O_2 and the added stress of the limited O_2 diffusion stimulates trophoblasts to proliferate, migrate, differentiate, and promote maternal and fetal vascular contribution to the placenta [17]. In the first trimester, establishment of blood flow into the intervillous space is associated with a burst of oxidative stress at a time when placental vascular development is occurring [18].

HIF-1 is a heterodimeric transcript factor which consist of two subunits like HIF-1 beta subunit is constitutively expressed, HIF-1 alfa subunit is regulated by oxygen levels. HIF-1 is stable under hypoxic conditions but at normoxic conditions it will degradeed rapidily. After activation, HIF-1 translocates to the nucleus it induces the transcription of numerous downstream genes via their hypoxia response elements. Vascular endothelial growth factor (VEGF) is one of the target gene.

Recent reports [19] suggest that pre-eclampsia (PE) is associated with a Th1 predominant profile and it may considered as a failure of tolerance system allowing the second physiological trophoblastic invasion. This Th1 predominant immunity is closely related to inflammation, endothelial dysfunction and poor placentation [10,20].

In pathophysiology of preeclampsia a deficiency of regulatory T cells may play a role. Immunological data [21] have shown that the increased levels of T CD4 (+) 45RO (+) and T CD8 (+) CD25 (+) cells can suggest the activation of CD4 (+) and CD8 (+) T lymphocytes in pre-eclampsia. It seems possible in pre-eclampsia activated T lymphocytes are associated with deficiency of T regulatory cells. Breakage of maternal tolerance to the fetus may takes place due to decreased number of T (reg) cells in pre-eclampsia.

Cindrova-Davies et al. [22] have shown that powerful inducer for placental oxidative stress, inflammatory cytokines, angiogenic regulators, and heat shock proteins as result of acute hypoxia/reoxygenation process is labor. These reports are consistent with initiating cause of perfusion being. Intermittent utero-placental perfusion associated with Uterine contractions during labor. As observed in preeclampsia transcripts changed in the same direction at cellular level. Placenta responds similarly to the oxidative stress during labor and in preeclampsia.

Heat Shock Proteins (HSP) and Immune Function

HSPs are evolutionarily ancient and highly conserved intracellular molecular chaperones. They are constitutively expressed in the cells, but are highly induced by different stresses such as heat, oxidative stress, oxygen radicals, or transformation. HSPs also perform immune functions. Degradation of cellular proteins, self and alien occured due to inherent property of binding non-covalently to the peptides generated within cells. HSP-peptide complexes are intracellular under normal conditions and have a protective function. On the other hand, extracellular located or membrane-bound HSPs mediate immunological functions [23]. Oxidative stress is at the heart of the regulation mechanisms maintain a balance between efficient regeneration and proper control of stem cell function. Too much activity of stem cell can cause diseases like cancer so, activity of stem cells has to be controlled carefully. Under normal health conditions Cellular stress may give misfolded or mutated "self" proteins, which results in the presentation of sequences from the immune system. This cryptic epitopes of "self" proteins are considered as endogenous danger signal and also "nonself" or new peptides by the host's immune system

because during positive and negative selection in the thymus the fact T cells were not exposed to these epitopes. A large variety of chaperoned antigenic peptides are tumor antigens. Repertoire of tumor antigens are carried out by HSPs, some of these antigens are cryptic epitopes and this can be seen by the host's immune system as nonself peptides [22]. The aforementioned outcomes is a crux part for high temperature stun proteins in immunological phenomena like initiation of antigen exhibiting cells, roundabout presentation (or cross-preparing), and escorting of peptides throughout antigen presentation [24]. Yosino et al. [25] in their research conclude that HPS70-reactive $CD4^+$ T cells exist in tumor tissue. These tumor-infiltrating lymphocytes (TIL) recgnize stressed cells and seem to play a Th1-like role that may support antitumor T cell responses at local tumor sites.

The Role of CD40/CD40L in Regulating Immune Response, Epithelial Cell Growth and Differentiation and in Induction of Cell Cycle Blockage and/or Apoptosis of Epithelial Cancer Cells

Young et al. [26] have shown that the wide interpretation of CD40 in typical epithelial units and carcinoma units proposes that this receptor has vital, supplemental impacts past that of managing resistant reactions. The major ligand for the external domain of CD40 is CD154 (CD40L), a member of the TNF superfamily. T lymphocytes will initiated by the most bounteous origin of CD154. B cell expansion and differentiation directs by CD40 ligand face to face times. This receptor plays on other cell sorts, especially those of nonhemopoietic origin. CD40 is expressed on human epidermal basal cells and also CD40 ligation may be a signal for limitation of cell growth and induction of differentiation [26]. When ligated CD40 is on human breast, ovarian, cervical, bladder, non-small cell lung, and squamous epithelial carcinoma cells a direct growth-inhibitory effect can be found. Induction of cell cycle blockage and/or apoptosis is related to this effect. The CD40/CD154 couple plays a critical role in humoral and cellular immune response. The CD40/CD40L system, a key regulator and amplifier of immune reactivity is required for antigen-presenting cell activation as it induces costimulatory molecules and cytokine synthesis. Thus, CD40–CD40L interactions are crucial in the delivery of T cell help for CTL priming. An expected rival of CD40/CD154 cooperation is solvent type of CD40 (sCD40) which has been demonstrated to hinder tying of CD154 to CD40 in vitro. Inhibition of antibody production occurs due to high levels of sCD40 could compete for the ligation of membrane CD40 on CD154. An important way of control is a rapid up- and down-regulation of CD154 on the surface of T cells. CD154 could be communicated upon T-cell receptor engagement fast this is first stage and CD40 itself commits to down-managing CD154 representation on T units as maintained face to face time between CD40/CD154 results endocytosis of the ligand this is second stage. Soluble form of CD40 production is also invovled in demonstrating a potential antagonistic role of CD40 sCD40 in immune response. This mechanism would be considered that the major way of CD40/CD154 interaction is down-regulated. The process which up-regulates the production of soluble receptors that compete with the membrane receptor for ligand binding (shedding) is important and it also reduces the amount of surface receptor. Antagonistic activity of sCD40 on the CD40/CD154 interaction and shedding mechanism expressed an important negative feedback on control of CD40 functions [27,28]. In absence of costimulation, fully differentiated Th1 effector cells produce suppression by stimulation of antigen. Independent costimulating of T-Cells and upregulating of CD80/CD86 molecules on APCs will regulate T-Cell activation.

In the light of the above studies, this paper provides further a review and a retrospective analysis in summary of our previous published [1] and unpublished investigations to answer the question whether Placenta Suspension prepared upon Filatov's method from the allogeneic human placenta-tissue after a live full-term delivery, expresses trophoblast cross-reactive antigens present on certain types of trophoblast cells and on transformed cells in the sense that both types of cells express embryonic-like features.

Preventive Cancer Vaccine Based on Placental Stem/Progenitor Embryonic-Like Cells of Full-Term Human Placentas Delivered after Spontaneous Labor

Background

In view of the supposition that advancing placenta partitions indistinguishable development components, antigenic determinants, and safe-escape lands with tumor units, immunological cross-reactivity between placental antigens and tumor antigens was invesigated.

Methods summary

In the eighth decade of the last century extensive clinical delayed-type hypersensitivity (DTH) skin tests to an intradermal injection in the 1/3 upper anterior surface of the forearm of 0.2 ml of a pharmaceutical allogeneic human Placenta Suspension (ph PS) (Suspensio Placentae pro injectionibus, Odesski zavod Hinfarmapreparatov, Odessa, former USSR), prepared upon Filatov's method from cryopreserved and mechanically disrupted of full term human placentas delvered after spontaneous labor were performed in obstetrical (150 pts.), gynecological (175 pts.) patients with different clinical conditions.

All tests were made under institutional approval and with documented informed consent.

DTH response is an invulnerable method appraisal that measures the presence of enacted T-units that recognise certain substances. Comparative to the mantoux skin test for tuberculosis, a mononuclear unit reaction is mounted at the post of antigen challenge if the patient has prior T unit resistance.

Results

239 patients with different clinical conditions, such as hypertensive disorders during pregnancy (98 pts. with preexisting hypertension, gestational hypertension, preeclampsia, superimposed preeclampsia), abnormal perimenopausal and menopausal uterine bleeding (141 pts.) have shown positive cutaneous delayed-type hypersensitivity (DTH) reactions to phPS.

According to the clinical and histopathlogical diagnosis, two large groups have resulted in which obstetrical and gynecological patients with different clinical conditions have shown positive cutaneous DTH-response to phPS: an aggregation of kindhearted obstetrical and gynecological clinical conditions having as histopathological substratum adjustable syncytiotrophoblast-cell hyperplasia (98 pts), or reactive/adaptive endometrial cell hyperplasia (76 pts.) and a group of different gynecological cancers (65 pts.).

Hypertensive Disorders in Pregnancy Stimulates Proliferation of Cytotrophoblastic Stem Cells That Adopt an Embryonic-Like Stem Cell Antigenic Profile

Syncytiotrophoblast hyperplasia is commonly seen in patients with hypertension, preeclampsia and occasionally diabetes. Traditionally

these clinical conditions have been associated with "placental insufficiency". A compromised maternal circulation in the intervillous space may create a state of true or relative hypoxia that stimulates proliferation of cytotrophoblast stem-like cells that differentiate into the syncytiotrophoblast on the villosities surface in order to increase the exchange area of the placenta. Hypoxic clinical conditions, such as arterial hypertension, diabetes, but also unopposed estrogen stimulation of endometrial growth are also seen in patients with perimenopausal or postmenopausal endometrial cell hyperplasia which have shown positive skin reaction to phPS.

The invulnerable reaction opposite phPS have indicated antigenc similitudes between standard placental and endometrial hyperplastic cells and diverse sort of growth cells since countless diseases receive an embryonic stem-like gene declaration design, it recommended that the profile of hypoxia-advertising placental and endometrial undifferentiated organism expansion is more in embryoniccells. In this way it positing that the hyperplastic cells in cytotrophoblastic unit hyperplasia and in plenteous endometrial development. As consequence of perfusion-restricted or dissemination-restrained hypoxic clinical conditions, secure trademark traitls by reactivating genes typically communicated in developing trophoblast and in converting cells. The potentialities of regeneration of the cytotrophoblast are produced by remodeling of "cytotrophoblast stem-like cells" and the presence of "adult stem cells" in the endometrial mesenchyme highlights their importance in the regenesis and remodeling of endometrial structures.

Labor Intermittent Hypoxia Shifts the Antigenic Profile of Induced Placental Proliferating Stem Cells to One that is More Embryonic-Like

We hypothesized also that labor intermittent hypoxia-induced placental stem/progenitor embryonic-like cells of placenta could immunize after birth to generate immune response against a variety of antigens that are shared by different kinds of epithelial cancers. This raises the electrifying conceivability of advancing a prophylactic vaccine fit for forestalling the manifestation of diverse sorts of malignancies in people.

Hypoxia has indicated to play a vital part in favoring the undifferentiated cell state, and yet in pushing undifferentiated cell expansion effect of the capacity of grown-up undeveloped cells equipped for genomic reprogramming upon presentation to a novel hypoxic nature to embrace the outflow profile to one that is more embryonic-like and express some however not all embryonic undifferentiated cell markers (multipotent non-hematopoietic foundational cells). Additionally, tumor conversion is intimately coupled with the "presence" of embryonic foundational microorganism-like qualities, in that both overexpress oncofetal developmental antigens (OFA) and hand-off only on glucose metabolism for their force needed for fast cell development and division.

Persistent growth and accelerated oxygen consumption by hyperplastic placental cells and hyperplastic endometrial cells in a hypoxic microenvironment, a basic shift in energy metabolism is accompanied by appearance of heat shock proteins (HSPs), increase of fetal isoenzymes and of membrane glycoproteins (oncofetal antigens, OFA), which, as result of their overexpression/amplification may induce a host immune response. Both types of cell undergo deprogramming to a embryonic-like stem cell state similar in phenotype to cancer cells. As one unit, the aforementioned findings infer that HIF targets might fill in as crux inducers of a dynamic state of stemness in pathologic conditions and that tissue recovery after damage seems to reiterate the pathway of embryonic tissue advancement.

The up-modulation of OFA gene expression in hyperplastic placental and endometrial cells and in tumors might be related to the requirement of proliferating cells for increased protein synthesis to face the new growth needs of these cells closely related to cell proliferation, that classified it as oncogene and that by overexpression/amplification becomes immunogenic.

Over expression changes on a proteine into immunologically conspicuous antigen have not been fully illustrated. Above all likely than not the overexpressed protein either ends up being all the more unvaryingly displayed to the safe framework or the thickness of presentation crosses the limit required for T unit stimulation.

The host DCs which are proliferative cells intrinsically more cross presentable will produce protective antitumor activity. Tumor cells may produce over expressed antigens.

Preeclampsia is Characterizeed by Hypoxia-reactivated Placental Stem/Progenitor Cells Reverted to a Proliferative Embryonic Stem-like State and a Prdominant Th1-cell Immune Profile

Concerning the preeclampsia, reactivation of the cytotrophoblast as result of placental hypoxia and unusual immune response to self-antigens of the emerging trophoblast, suggests that proinflammatory cytokines and vascular oxidative stress play a role in causing hypertension by activating multiple neurohumoral and endothelial factors and that ligation of CD40 on proliferating extravillous trophoblast stem/progenitor embryonic-like cells, by CD40 ligand (CD154) on $CD4^+$ T cells, may lead to limitation of cell growth and induction of incomplete differentiation and inadequate invasion of the trophoblast and thus, to ineffective vascular remodeling of the uterine spiral arteries that results in insufficient placental perfusion as well as widespread dysfunction of the maternal vascular endothelium [20].

In conclusion, it is assuming that $CD4^+$ T cells frequently recognize nonmutated "self" antigens that are overexpressed by both cytotrophoblastic and endometrial stem cells, but also growing tumor cells. Since patients with positive skin DTH-reaction to phPS can harbor $CD4^+$ T cells specific for non-mutated, differentiation antigens overexpressed by hyperplastic placental embryonic-like stem cells and neoplastic cells, vaccination might reasonably be expected to amplify the frequency and strength of these pre-exsiting responses or perhaps induce some de novo reactions.

Placental Embryonc-Like Stem Cells of Human Full-Term Placentas Delivered After Spontaneous Labor Shares Antigens in Common With Different Kind of Epithelial Cancer Cells and Thus Phps Emerges as a Preventave Cancer Vaccine-Related Product

Labor-induced intermittent hypoxia promotes proliferation of placental stem/progenitor cells reverted to an embryonic-like stem cell state by expressing some but not all embryonic stem cell markers and thus, full-term human placenta delivered after spontaneous labor (afterbirth placenta) based on proliferating cord blood-derived embryonic-like stem cells, hypoxia-induced multipotent non-hematopoietic stem cells mixed with other proliferating placental matrix-stem cell populations could immunize to generate immune response against a variety of antigens that are shared by different kind of

epithelial cancers. The abundance of HSPs in the undifferentiated state of proliferating placental embryonic-like stem cells may overexpressed OFA antigens in these cells intrinsically more cross-presentable to the host DCs for generating protective antitumor `activity both in mother and in newborn. Such a model, although attractive, remains speculative. However, together these findings suggest that the phPS could be considered as a placental embryonic-like stem cell vaccine and that the cutaneous DTH-reaction to phPS is a Th1-cell response to antigens expressed by these cells and which are also cross-reactive with antigens expressed by different epithelial cancer cells. This feature of phPS qualifies it as a multiepitope vaccine-related product that may be used as universal preventive cancer vaccine. Through imparting exogenous and activating endogenous anti-tumor mechanisms within normal healthy individuals by utilizing universal, non-mutated oncofetal antigen vaccines, e.g., phPS vaccine based on embryonic-like stem cells, the immune system is able to destroy nascent cancerous cells before accumulating mutational changes are occuring. The use of overexpressed proteins, as tumor-associated antigens yields rational targets for specific immunoprevention.

In cancer prophylaxis, we need to destroy just a single cell - the one transformed cell that may give rise to malignancy. Among tumor associated antigens are antigens upregulated in malignant transformation e.g. oncofetal antigens–carcinoembryonic antigen (CEA), alphafetoprotein (AFP), growth factor receptors-Her2/neu, telomerase and p53. A prophylactic vaccination that involves a number of shared antigens may represent a strength of this vaccination approach in as much as immune recognition of multiple antigens would make it less likely for nascent tumor cells to escape immune detection and destruction.

Discussions

A novel hypoxic environment shifts the antigenic profile of adult stem cells to one that is more embryonic-like

As typical tissues: foundational microorganisms, travel-opening up units and developed cells malignancies have the comparable utilitarian unit inhabitant totals and it is introduced in a result of undifferentiated organism hypothesis of root of growth. In tumor tissues travel-enhancing cells that don't differentiate developed units amass in malignancy, in standard tisue they can differentiate. In this way, Cancer tissue contrasts from standard tissue [29]. Unrestained development and quickened oxygen devouring by burgeoning stem/progenitor (travel-enhancing) cells of standard tissue, or at separation from veins demonstrating a hypoxic microenvironment, shows gene interpretation marks trademark of human embryonic stem-like cells, or by advertising genomic insecurity drives conversion of stem/progenitor cells additionally into a stable "para-embryonal" condition and consequently, both might be distinguished as risky by the resistant framework. The introduce that growth units part the declaration of oncofetal antigens with stem/progenitor embryonic-like units and that the invulnerable reaction opposite the proposed antigens is cross-defensive opposite disease and that the sickness just shows if invulnerable reaction are discouraged in securing opposite conversion, the utilization of overexpressed proteins of the proposed stem/progenitor embryonic-like cells, as tumor-partnered antigens yelds normal focuses for particular tumor immunoprevention.

The soluble forms of membrane molecule CD40 (sCD40) may have a role in modulating antitumor responses

Systemic immunity to some gynecological tumors and to syncytiotrophoblast hyperplasia as measured by skin delayed-type hypersensitivity response to phPS strongly support the notion that the host immune system, harboring specific $CD40^+$ T cells, recognizes the presence of the reexpressed and overexpressed oncofetal antigens (OFAs) on transformed stem/progenitor cells, or on placental stem/progenitor cells reverted to a proliferative embryonic-like stem cell status as result of genomic reprogramming during labor exposure to a novel hypoxic environment, and that can remain alive for days after delivery.

Unfortunately, this confirmation that the invulnerable framework can distinguish spontaneous tumors, is for no continuing on profit to the patient. It gives the idea that it is the safe framework itself that is preventing its particular movement of resistance with impedance with inhibitory immunological checkpoints regulating T cell initiation.

The ways tumors become unrecognizable to the immune system are various and numerous.

Darrasse-Jèze et al. [30] emphsize that the relative activation speed of self-specific memory Tregs (regulatorys) versus that of tumor-specific naive Teffs (effector) at the time of tumor emergence dictates tumor outcome. Thus, $CD4^+$ -cell responses can also elicit not only stimulatory but also suppressive immunity. It is becoming clear that tregs play a pivotal role in the tumor progression and the suppression of tumor immunity. Furthermore, effector/memory regulatory T cells increased as the primary tumor progressed. Data suggest that effector/memory Treg cells are responsible for the loss of concomitant tumor immunity associated with tumor progression [30].

As of late it was indicated that T cell accommodate for CTLs is basically reliant on communication between CD40L communicated by Th cells and CD40 communicated by APCs.

CD40-CD154 interactions are of central importance and pivotal in the induction of cellular immune responses to many antigens [26]. Numerous lines of confirmation show that CD40 indicating is part of a vital pathway in T cell–dependent antigen introducing cell (APC or DC) enactment. CD40 ligation on antigen-presenting cells (APCs) by CD40L (CD154) on $CD4^+$ T cells was found to be necessary to induce $CD8^+$ T cell priming by APC. This pathway play a critical role in the induction type-1 cytokine responses of protective immunity. Dendritic cell (DC) exist in two stages: Immature and mature. Mature DC cells prime T cells, whereas immature DC can induce tolerance to the presented antigens. The immature DCs are non-immunologically quiescent; they have been shown to induce T cell tolerance *in vivo* through the induction of T cell energy, direct depletion of T cells, or by generation of regulatory or suppressor cells that block the function of other T effector T cells. For full development and aquisition of T cell preparing limit DCs need to be "authorized", which can happen by accepting star-provocative signs in the type of CD4 T cell "assist" with CD40-CD40L collaboration. Adequate activation of T cells requires multiple signals from the DC to the T cell. MHC-peptide recognised by the T cell recptor (TCR) on the T cell is crucial for initial activation, but will lead to anergy or non-responsiveness without appropriate additional costimulation provided by interaction between CD28 on the T cell and B7.1/B7.2 on the DC. With the help of $CD8^+$ cell priming and maintenance CD4 Tcells mediated killing and affect angiogenessis by activating various cells into tumor environment.

Innate immune cells which are critical for the first line of defense against tumorigenesis are natural killer (NK) and natural killer T (NKT) cells. Although NKT cells shows NK-like cytolytic activity. Due to their activation rapid production of IFN-γ and expression of CD40L

will occur, this result in the activation of CD40-expressing APCs and production of cellular and humoral immune responses.

Along these lines, it has been demonstrated that a prevailing pathway of $CD4^+$ assistance is through antigen-putting forth cell (APC) initiation with engagement of CD40 by CD40 ligand (CD154) on NKT units and $CD4^+$ T cells. CD40L is mainly expressed transiently on activated $CD4^+$ helper T cells subsequent to recognition of MHC–peptide complexes. It is required for antigen-presenting cell activation as it induces costimulatory molecules and cytokine synthesis. It has been suggested that in absence of a strong "danger" signal at this time contributes to the ability of newly forming tumors to avoid recognition by the host immune response. Finally, priming of $CD8^+$ cytotoxic T lymphocytes generally requires help provided by $CD4^+$, and the CD40–CD40L interaction was shown to be essential in the CTL priming via activated DCs [31].

Likewise, CD40 is communicated and utilitarian on human epithelial cells, and on the aforementioned cells, CD40 ligation might be a sign for confinement of cell development and actuation of differentiation [26,27]. Ligation of CD40 on tumor units was additionally discovered to generate a straight development-inhibitory impact by way of unit cycle blockage or alternately apoptosis with no clear symptoms ordinary cells. Yet, the typical enemy of CD40/CD154 collaboration is the dissolvable manifestation of CD40 (sCD40) which has been demonstrated to restrain the coupling of CD154 to CD40 *in vitro*. Abnormal amounts of sCD40 in tumors bringing about restraint of neutralizer handling because of ligation of layer CD40 on CD154.

Hock et al. [32] have shown that CD40 plays a discriminating part in immunoregulation, inferring that sCD40 may have a part in balancing antitumor reactions and likewise might be an of service prognostic marker. The release of soluble forms of membrane molecules provides an important mechanism by which cells can either enhance or inhibit the signals delivered by their respective membrane-bound counterparts, suggesting that *in vivo* release of functional sCD40 would be immunomodulatory. The release of sCD40 by the immune system and/or by malignant cells provides a potentially powerful mechanism for regulating antitumor responses by modulating the interaction of mCD40 with its ligands.

On the other hand for the effective activation of T cells engagement of two separate T-cell receptors are required. One is Foreign peptide antigen-MHC complexes binded with antigen-specific T-cell receptor (TCR) and another one is B7 (CD80/CD86) costimulatory molecules binded with CD28 on the surface of antigen-presenting cells (APC). Simultation engagement of T cell surface with different specific ligand results in cell activation. Distinct T-cell receptor (CTLA-4) give an inhibitory signal to T cell activation by binding with B7 molecules. For initiating the T-cell responses CD86 is important, and for maintaining these immune responses CD80 is more significant [33].

This interpretation shows that CD28 functions are not as "on-off" switch these functions are like "rheostat" which, depending on the strength and/or duration of its engagement by B7 molecules. It also can display a degree of plasticity in the intracellular signals it generates [33].

Most $CD4^+$ T cells belong to either the Th1 or Th2 subsets. However ~10% of them do not. These so-called T-regulatory (Treg) cells. The CTLA-4 molecules on Treg cells bind very tightly to the B7 molecules on antigen-presenting dendritic cells and B cells. Once bound, they kill the target (by secreting perforins). Treg cells can also kill cytotoxic T lymphocytes (CTL) and natural killer (NK) cells.

CTLA-4 have 50–100-fold higher affinity to B7 than CD28. For preventing Subsequent activation of T cell in effector T cell and CD28 signaling Tcell will compitatively engaged with available B7 molecules on APCs [34,35]. In a variety of experimental systems and one of the major paradoxes of tumor immunology we can obsereve the co-existence of tumor specific immunity with progressing tumor. It creates the impression that the resistant framework itself that its particular action of resistance. This conduct imprints a closeness to the incipient organism and of malignancy [36].

The above observations lead to the conclusion that reexpression and overexpression of the trophoblast cross-reactive antigens present on placental hyperplasic cells, but also on neoplastic cells and continuously shedding of CD40 (sCD40) represent an adaptive response of these cells to natural selection pressures as a biological response to resist immunological recognition and rejection by the host. Increased levels of soluble CD40 receptor (sCD40) which reduces availability, impede the immune system from mounting appropriate humoral and cell-mediated responses against precancerous cells will Inhibiti the CD/E (expressing) 40 pathway by given opposing movement of sCD40 on the CD40/CD154 collaboration, this shedding component may speak for an imperative negative input control of CD40 capacities, proposing that sCD40 may have a part in balancing a prior or all over again against-tumor reactions by way of obstruction with inhibitory immunological check focuses regulating T cell initiation.

Placental stem/progenitor embryonic-like cells based cellular vaccine an efficient immuno preventive of human malignancies

To overcome these escape mechanisms and to acquire the goal of an optimal adaptive immune response particularly to reexpression of embryonic proteins that begins to be overexpressed in tumor cells early in their transformation and which can be considered as non-self by the immune system, it was proposed a vaccination strategy design by intradermal injection of a pharmaceutical human allogeneic Placenta Suspension (phPS), prepared upon Filatov's method and admixed with BCG Vaccine ("danger" signal) in normal healthy individuals to induce activated/memory T effector cells (amTeffs). This cross-priming of the tumor cells overexpressed antigen-specific response by potent APC is a major mechanism of the developing integrated endogenous immune response, thereby shifting the balance from tolerance to activation induction, and/or rejuvenating functionally inferior responses of the exausted T cells.

Activated Th1 cells have longevity compared with other activated immune cells (APCs and CTL) and are conventionally viewed as being responsible for immune memory, capable of revitalizing the immune response if a specific antigen is reencountered, including promtly function of CD40/CD40L interaction, prior to the release of sCD40 by the immune system and/or by transformed cells. The presence of activated/memory T effector cells (amTeffs) at the time of tumor emergence shifts the Treg/Teff balance toward efficient antitumor immune response. Alternatively, or in addition, the CD4 T cells may be required for activation of macrophages and dendritic cells, an event crucial for killing of transformed cells. This antisupressive approach reverses the host'immune factors that confer a survival advantage to tumor emergence and requires an intact immune system to function.

Advantage of Bacillus Calmette Guerin-Vaccine (BCG-Vaccine) is that is an immunogenic compound,it recognized foreign body naturally and known to induce migration of APCs to the site of delivery. APCs will respond to the adjuvant stimulation and are

able to coincidentally capture and process placental antigens to the inflammatory milieu.

Becker et al. [35] by using macrophages and denritic cells CD40 mediating the uptake of exogenous Hsp70–peptide complexes and it is a cochaperone-like receptor. For the generation of potent T cell immune responses against self-tumor Ags, Hsp70 Ag from Mycobacterium tuberculosis was shown to induce Th1-polarized cytokine responses and activate DCs via binding with CD40. Although without activation of dendritic cells (DCs) Ag targeting alone to induce tolerance. Vaccines expressing self-tumor Ags are rendered immunogenic if targeted to the APCs using mycobacterial Hsp70 Ag [35]. And eliciting long-term protective $CD8^+$ T cell-mediated memory responses effective in killing the emerging tumor cells.

At the same time the immune response is mediated through the release of different cytokines which can influence the synthesis and actions of one another in the setting of an immunoregulating cytokine network, shaping an environment in which the presence of active/memory T effector cells (am Teffs) at the very time of tumor emergence, are able to bypass the tumor immunity mediated by self-specific memory regulatory T cells. These two aspects of a preventive vaccination with multiepitope phPS/BCG-Vaccine might be useful for generating an immune response against a broad-spectrum of cancers, thus serving as a universal cancer vaccine.

The plausibility of prompting lifelong assurance opposite tumors by immunization at the most punctual indications of its growth has the potential to create a memorable ideal model transformation in the avoidance of tumors.

The justification for aversion is solid in light of the fact that, in that setting one bargains with an insusceptible framework that is not, one or the other disabled by tumor-and medication-affected suppression nor tolerant to tumor-cohorted antigens that have been experienced without right presentation and costimulatory/danger signs. On the other hand, a future success of cancer prevention will depend on how effectively a preventive vaccination strategy simultaneously acts on emerging pretumor cells as well as on its microenvironment [37].

Conceptually, to avoid the regulatory T cells' immune suppression that develops in tumor-bearing patients, vaccination with a pharmaceutical allogenic human Placenta Suspension prepared upon Filatov's method, after a "danger signal" is added e.g. BCG-Vaccine, would be capable of eliciting immunological responses in normal healthy individuals, not only to marker antigens shared between the Placenta-Suspension preparation and neoplasia, but also by introducing a new environment of T-cell-induced cytokines, that provide a more "complete" immune response, to prevent tumor development far into future, by inhibition, or by elimination of transformed cells at their earliest manifestation. Thus, active immunoprevention uses the host's immune cells and requires an intact immune system to function.

Using of isolated labor intermittent hypoxia-induced placental stem/progenitor embryonic-like cells of afterbirth placenta per se, or of phPS prepared upon Filatov's method, as a vaccine-related product for a preventive cancer vaccine, warrants further investigation.

The above speculation is climbing as a for the experimental neighborhood in the trust that it will create an examination of this matter.

References

1. Corocleanu M (1981) Humoral and Cellular Reactions to Placental Antigens in Women with Pathological Pregnancies and Cancer Patients. Rev Roum Biochim 18: 7-13.
2. Corocleanu M (2008) A possible "universal" cancer vaccine that might cause an immune response against emerging cancer cells that originate from any tissue. Med Hypotheses 70: 381-383.
3. Redman CWG (1986) Immunology of the placenta. Clin Obstet Gynaecol 16: 469-499.
4. Hamilton MS (1983) Maternal immune responses to oncofetal antigens. J Reprod Immun 5: 249-264.
5. Sarandakou A, Protonotariou E, Rizos D (2007) Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 44: 151–178.
6. Monk M, Holding C (2001) Human embryonic genes re-expressed in cancer cells. Oncogene 20: 8085-8091.
7. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.
8. Coggin JH Jr, Barsoum AL, Rohrer JW, Tucker JA, Dyess DL (2001) Materno-fetal immunobiology hypothesis: immature laminin receptor protein is a primitive, species conserved, universal embryonic T and B cell immunogenic providing both maternal and fetal protection. Mod Asp Immunobiol 2: 84-91.
9. Coggin JH Jr, Anderson NG (1974) Cancer, differentiation and embryonic antigens: some central problems. Adv Cancer Res 19: 105-165.
10. Siegel S, Wagner A, Friedrichs B, Wendeler A, Wendel L, et al. (2006) Identification of HLA-A*0201-Presented T Cell Epitopes Derived from the Oncofetal Antigen-Immature Laminin Receptor Protein in Patients with Hematological Malignancies. J Immunol 176: 6935-6944.
11. Rohrer JW, Barsoum AL, Dyess DL, Tucker JA, Coggin JH Jr (1999) Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes. J Immunol 162: 6880-6892.
12. Lee MW, Jang IK, Yoo KH, Sung KW, Koo HH (2010) Stem and progenitor cells in human umbilical cord blood. Int J Hematol 92: 45–51.
13. Zhong Z, Patel AN, Ichim TE, Riordan NH, Wang H, et al. (2009) Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med 7: 15.
14. Fryer BH, Simon MC (2006) Hypoxia, HIF and the Placenta. Cell Cycle 5: 495-498.
15. Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677-684.
16. Adelman DM, Gertsenstein M, Nagy A, Simon MC, Maltepe E (2000) Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses. Genes Dev 14: 3191-3203.
17. Myatt L, Cui X (2004) Oxidative stress in the Placenta. Histochem Cell Biol 122: 369-382.
18. Vaiman D, Mondon F, Garcès-Duran A, Mignot TM, Robert B, et al. (2005) Hypoxia-activated genes from early placenta are elevated in Preeclampsia, but not in Intra-Uterine Growth Retardation. BMC Genomics 6: 111.
19. Saito S, Sakai M (2003) Th1/Th2 balance in preeclampsia. J Reprod Immunol 59: 161-173.
20. Darmochwal-Kolarz D, Saito S, Rolinski J, Tabarkiewicz J, Kolarz B, et al. (2007) Activated T lymphocytes in pre-eclampsia. Am J Reprod Immunol 58: 39-45.
21. Sasaki Y, Darmochwal-Kolarz D, Suzuki D, Sakai M, Ito M, et al. (2007) Proportion of peripheral blood and decidual CD(4+) CD25(bright) regulatory T cells in pre-eclampsia. Clin Exp Immunol 149: 139-145.
22. Cindrova-Davies T, Yung HW, Johns J, Spasic-Boskovic O, Korolchuk S, et al. (2007) Oxidative stress, gene expression, and protein changes induced in the human placenta during labor. Am J Pathol 171: 1168-1179.
23. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C (2007) Intracellular and extracellular functions of heat shock proteins: repercussion in cancer therapy. J Leukoc Biol 81: 15-27.
24. Srivastava P (2002) Interaction of Heat Shock Proteins with Peptides and Antigen presenting Cells: Chaperoning of the Innate and Adaptive Immune Responses. Annu Rev Immunol 20: 395-425.

25. Yoshino I, Goedegebuure PS, Peoples GE, Lee KY, Eberlein TJ (1994) Human Tumor-infiltrating CD4+ T cells react to B cell lines expressing heat sock protein 70. J Immunol 153: 4149-4158.

26. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW (1998) CD40 and epithelial cells: across the great divide. Immunol Today 19: 502-506.

27. Péguet-Navarro J, Dalbiez-Gauthier C, Moulon C, Berthier O, Réano A, et al. (1997) CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation. J Immunol 158: 144-152.

28. Contin C, Pitard V, Itai T, Nagata S, Moreau JF, et al. (2003) Membrane-anchored CD40 Is Processed by the Tumor Necrosis Factor-alpha-converting Enzyme. Implications for CD40 signaling. J Biol Chem 278: 32801-32809.

29. Stewart Sell (2008) Alpa-fetoprotein, stem cells and cancer: how study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to raffirmation of the stem cell theory of cancer. Tumor Biol 29: 161-180.

30. Darrasse-Jèze G, Bergot AS, Durgeau A, Billiard F, Salomon BL, et al. (2009) Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest 119: 2648-2662.

31. Gorelik E (1983) Concomitant tumor immunity and the resistance to a second tumor challenge. Adv Cancer Res 39: 71-120.

32. Hock BD, McKenzie JL, Patton NW, Drayson M, Taylor K, et al. (2006) Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer 106: 2148-2157.

33. Prilliman KR, Lemmens EE, Palioungas G, Wolfe TG, Allison JP, et al. (2002) Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL. J Immunol 169: 4094-4097.

34. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206: 1717-1725.

35. Becker T, Hartl FU, Wieland F (2002) CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol 158: 1277-1285.

36. Vasilevko V, Ghochikyan A, Holterman MJ, Agadjanyan MG (2002) CD80 (B7-1) and CD86 (B7-2) are functionally equivalent in the initiation and maintenance of CD4+ T-cell proliferation after activation with suboptimal doses of PHA. DNA Cell Biol 21: 137-149.

37. Finn OJ, Forni G (2002) Prophylactic cancer vaccines. Curr Opin Immunol 14: 172-177.